Emergent (NYSE:EBS) already sells a 4mg naloxone nasal ... qualified purchasers can buy the product in bulk, according to a statement.

Welcome to Emergent BioSolutions Inc. fourth quarter 2024 earnings conference call. At this time, all participants are in a ...

Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland’s next ...

In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent ...

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...

Turning to Slide 2. During today's call, Emergent may make projections and other forward-looking statements related to their business, future events, their prospects, or future performance.